Company: RGNT
Filing Date: 2025-07-07
Form Type: F-1/A
Source: 0001213900-25-061821
Chunk: 269

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-07-07
Form: F-1/A
Chunk 269
---
| d. | Deferred income taxes: |

Deferred income taxes reflect the net
tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the
amounts used for income tax purposes.

<div align='center'>F-20</div>

REGENTIS BIOMATERIALS LTD.

NOTES TO FINANCIAL STATEMENTS

U.S. dollars in thousands, except share and per share data

| NOTE 8:- | TAXES ON INCOME (Cont.) |

Significant components of the Company’s
deferred tax assets are as follows:

| Deferred tax assets:                                                           |     | December 31, 
 2024         |        |   |     | 2023 |        |   |
|:-------------------------------------------------------------------------------|:----|:-------------|-------:|:--|:----|:-----|-------:|:--|
| Net operating loss carry forward                                               |     | $            | 38,940 |   |     | $    | 40,064 |   |
| Deferred tax asset on capital loss carrying forward before valuation allowance |     |              |  8,956 |   |     |      |  9,214 |   |
| Valuation allowance                                                            |     |              | (8,956 | ) |     |      | (9,214 | ) |
| Net deferred tax asset                                                         |     | $            |      - |   |     | $    |      - |   |

In assessing the realization of deferred
tax assets, management considers whether it is more likely than not that all or some portion of the deferred tax assets will not be realized.

The ultimate realization of the deferred
tax assets is dependent upon the generation of future taxable income during the periods in which temporary differences are deductible
and net operating losses are utilized. Based on consideration of these factors, the Company recorded a full valuation allowance as of
December 31, 2024 and 2023.

| e. | Income tax expense (benefit): |

The components of profit /(loss) before
tax and a reconciliation of the Company’s theoretical statutory tax benefit to income tax benefit is as follows:

|                                                                                     |     | Year Ended   
 December 31, |   2024 |   |     |   |  2023 |   |
|:------------------------------------------------------------------------------------|:----|:-------------|-------:|:--|:----|:--|------:|:--|
| Income (loss) before taxes